If you are pregnant, or actively trying to conceive, and you are currently using a peptide product of any kind, the honest default answer is: stop and talk to your OB before you continue. That is not overcaution. Almost no therapeutic peptides have been studied in pregnant humans, and "no studies" does not mean "safe to use." It means unknown risk — and unknown risk during pregnancy is not a gamble most physicians or their patients should be willing to take without a specific medical reason that outweighs that uncertainty.
This article explains why pregnancy is the most cautious context in all of peptide pharmacology, which peptides are actually approved for use during pregnancy, which carry explicit contraindications, and how to think about nursing considerations when the information is sparse. It is not a substitute for a conversation with your obstetrician. That conversation is the point.
Summary: The Short Version for a High-Stakes Situation
Drug trials almost universally exclude pregnant participants for ethical reasons, so the evidence base for most medications in pregnancy is thin by design. Peptides are no exception — and in many cases the gap is wider than for conventional small-molecule drugs, because many therapeutic peptides have only recently entered widespread use.
The situation breaks down into three tiers.
Tier 1 — Physician-supervised, pregnancy-approved use: Insulin (all formulations) for gestational diabetes is the clearest example. These are not wellness decisions. They are managed by a maternal-fetal medicine specialist or endocrinologist who has weighed documented benefit against documented risk.
Tier 2 — Explicit contraindication per prescribing label: GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) carry explicit pregnancy contraindications and manufacturer recommendations to discontinue at least two months before attempting conception. Bremelanotide (Vyleesi) is explicitly contraindicated in pregnancy per its FDA prescribing label.
Tier 3 — Unknown risk, default to avoid: BPC-157, GHRPs, growth hormone secretagogues (ipamorelin, CJC-1295, hexarelin), thymosin peptides, and essentially every other peptide sold through compounding or research chemical vendors. There is no human pregnancy safety data for any of these. "No evidence of harm" means "no evidence" — not clearance.
| Tier | Examples | Pregnancy Position |
|---|---|---|
| 1 — Approved under specialist care | Insulin, oxytocin (labor induction only), vasopressin for diagnosed DI | Use only under direct specialist supervision with documented indication |
| 2 — Explicit contraindication | GLP-1 agonists (semaglutide, liraglutide, tirzepatide), bremelanotide | Discontinue before conception per label; do not use during pregnancy |
| 3 — Unknown, default avoid | BPC-157, ipamorelin, CJC-1295, hexarelin, TB-500, thymosin alpha-1, all compounded unapproved peptides | No human pregnancy data; default position is avoid and discuss with OB |
Why Pregnancy Is the Most Cautious Peptide Context
The standard rule in pharmacology is that a drug you cannot study in a vulnerable population gets a conservative label by default. Pregnancy gets the most conservative treatment of all, because two patients are involved and one of them has no say.
The FDA replaced its old letter-grade system (A/B/C/D/X) in 2015 with the Pregnancy and Lactation Labeling Rule (PLLR), which requires prescribing labels to include narrative summaries under three subsections: Pregnancy (8.1), Lactation (8.2), and Females and Males of Reproductive Potential (8.3). What the PLLR reveals, when you read actual peptide drug labels, is how thin the human evidence is. Section 8.1 for nearly every non-insulin peptide reads some variation of: "There are no adequate and well-controlled studies in pregnant women." That is regulatory language for "we do not know." It is not clearance.
Peptides add biological complexity beyond typical small-molecule drugs. Some cross the placental barrier; others are degraded quickly. Establishing which is true for a given compound requires reproductive toxicology studies at minimum, and ideally human pharmacokinetic data in pregnancy — neither of which exists for most compounded peptides. Growth factors and signaling peptides guide organogenesis during the first trimester with extreme precision; introducing exogenous compounds that mimic or interfere with those signals carries risks that cannot be quantified without data that does not yet exist.
If you are currently pregnant and using a compounded peptide: call your OB today.
Peptides That Are Approved for Use in Pregnancy
Insulin is the clearest example of a peptide used safely in pregnancy. It is a 51-amino-acid peptide hormone and the first-line pharmacological treatment for gestational diabetes mellitus (GDM), affecting roughly 6-9% of U.S. pregnancies. The evidence base spans decades of randomized trials and pharmacokinetic studies conducted specifically in pregnant women.
The key pharmacokinetic fact: insulin does not cross the placental barrier in meaningful amounts. The molecule is too large for simple diffusion, and there is no known active transport mechanism. The fetus produces its own insulin in response to glucose — which is why controlling maternal blood sugar is the treatment goal, not replacing fetal insulin. That property, established through direct clinical study, is what separates insulin from virtually every other peptide in the pregnancy discussion.
Oxytocin is used in clinical obstetrics for labor induction and postpartum hemorrhage management, but only under controlled hospital conditions with continuous monitoring — not as a wellness supplement. Desmopressin has been used in pregnancy for diagnosed central diabetes insipidus under specialist care.
The pattern across all Tier 1 uses is identical: a diagnosed medical condition, extensive human safety data, specialist supervision, monitoring in place. Wellness applications do not fit this model.
Peptides Explicitly Contraindicated in Pregnancy
GLP-1 receptor agonists are the most clinically relevant contraindicated peptide class for women of reproductive age right now. Semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro, Zepbound), and dulaglutide (Trulicity) are all in this group.
Manufacturers recommend discontinuing these medications at least two months before attempting conception. Animal reproductive toxicology data showed fetal growth restriction, skeletal malformations, and increased fetal deaths at exposure levels that were not toxic to the mother. Human data is limited by design — pregnant women were excluded from the major trials — but the animal signal is sufficient to establish the contraindication. A 2024 scoping review found "an absence of primary data about the role of GLP-1 RAs on the reproductive health of women of childbearing age" — the pregnancy contraindication stands precisely because the human evidence gap has not been filled.
Semaglutide has a half-life of approximately one week; full elimination takes roughly five weeks. Manufacturers round up to two months as a conservative margin. If you became pregnant while taking a GLP-1 agonist, contact your OB immediately and discontinue as directed.
Bremelanotide (Vyleesi), a synthetic melanocortin receptor agonist peptide approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, carries an explicit pregnancy contraindication in its FDA-approved prescribing label. Animal studies at doses approximating human therapeutic exposures showed fetal malformations and embryo-fetal toxicity. The label requires a negative pregnancy test before starting treatment and effective contraception during use.
Growth hormone secretagogues — GHRP-2, GHRP-6, ipamorelin, CJC-1295, hexarelin, MK-677 — have no approved human indication and no human pregnancy data. Growth hormone signaling plays a documented role in placental development and fetal growth regulation. The default is avoid.
BPC-157 has no published phase 2 or phase 3 clinical data in any human population and no FDA-approved indication. The FDA has placed it on its list of bulk drug substances presenting significant safety risks for compounding, barring its inclusion in compounded medications. "No evidence of harm" in the absence of human pregnancy studies is not clearance. Discuss with your OB and discontinue.
One point worth stating plainly: compounding does not equal safety in pregnancy. A compounded peptide is not an FDA-approved drug. The compounding process does not generate safety data; it only ensures (at best) that the product contains what the label says. That is a far lower bar than pregnancy safety.
Collagen Peptides: A Different Risk Tier
Collagen peptides are categorically different from the pharmaceutical peptides discussed above. Sold as food-grade supplements, hydrolyzed collagen is broken down to small amino acid chains and absorbed similarly to dietary protein. ACOG does not list collagen peptides as a substance to avoid in pregnancy. They reach the maternal circulation as free amino acids and dipeptides — not as intact signaling peptides with receptor activity — and there is no known mechanism by which food-derived collagen hydrolysates would disrupt fetal development.
That said, there is also no large controlled trial demonstrating a clear maternal or fetal benefit that an adequate prenatal diet does not already cover. If you are taking collagen powder while pregnant, mention it to your OB at your next visit. Low-risk is not the same as no need to disclose.
Nursing Considerations
Lactation introduces a different pharmacokinetic picture from pregnancy, but the evidence base for therapeutic peptides during breastfeeding is almost as thin.
For GLP-1 receptor agonists, manufacturer labels for semaglutide and liraglutide state that it is unknown whether these drugs are excreted in human breast milk and recommend against use during breastfeeding. Semaglutide has an elimination half-life of approximately one week; full elimination takes around five weeks after the last dose. Discuss the timing of resuming GLP-1 therapy after weaning with your OB. For bremelanotide, the FDA label explicitly recommends avoiding use during breastfeeding.
For unapproved compounded peptides — BPC-157, GHRPs, growth hormone secretagogues — there is no lactation data at all. The default is avoid and discuss with your OB before resuming. The general framework: if a peptide drug has an FDA prescribing label with a Section 8.2 lactation entry, read it and discuss with your physician. If the substance has no FDA-approved label, the absence of lactation data is itself the answer.
Talking With Your OB: What to Bring
Bring the product label or a photo of it. The specific compound name, dose, and route of administration matter. "Peptides" is not a complete answer; "injectable BPC-157 at 250 mcg daily from a compounding pharmacy" is.
Be specific about timing: when did you start, when did you stop, and were you using it during the first trimester — the window of highest risk for organogenesis-related effects? Ask directly whether you should be referred to a maternal-fetal medicine specialist for additional risk stratification.
If you are planning pregnancy and currently using a GLP-1 agonist for weight management or diabetes, discuss discontinuation timing with your prescribing physician well in advance. The two-month washout is not a same-day decision.
As covered in our guide to peptide side effects and risk factors, the highest-risk situations involve compounded or unapproved products with no clinical safety data. Pregnancy amplifies that risk to its maximum because a second patient — one who cannot consent — is involved.
Frequently Asked Questions
Can I keep taking collagen peptides while pregnant?
Collagen peptides from food-grade supplements are not listed as a substance to avoid by ACOG, and their risk profile is categorically different from pharmaceutical peptides with receptor activity. Mention it at your next OB visit. Most clinicians will note it as low-risk.
I was taking semaglutide (Ozempic/Wegovy) and just found out I am pregnant. What do I do?
Contact your OB or prescribing physician today. Discontinue as directed. Do not continue semaglutide during pregnancy. The two-month pre-conception washout recommendation exists because ideally you would have stopped before conception — not because brief exposure is certainly harmful, but because the risk is unknown and the label is explicit. Your OB will advise on monitoring.
What about peptide skincare products applied topically?
Topical peptides like matrixyl, argireline, and copper peptides are applied to intact skin at cosmetic concentrations and generally have negligible systemic absorption. This is a different risk tier from injectable or oral therapeutic peptides. The conservative position is to mention any active cosmetic ingredient to your OB or dermatologist.
Are GHRPs safe to continue while breastfeeding?
There is no human lactation data for any GHRP. The default is no — not because harm has been proven, but because unknown risk in a nursing infant is not an acceptable position without documented medical necessity. Discuss with your OB before resuming.
Is insulin the only safe peptide drug in pregnancy?
Insulin is the clearest example with extensive human pregnancy data and FDA-approved gestational use. Other peptide drugs are used in specific clinical circumstances — vasopressin analogues for diagnosed conditions, oxytocin in controlled hospital delivery — but these are specialist-supervised interventions. No unregulated or compounded peptide falls into the "safe in pregnancy" category based on current evidence.
Conclusion
Pregnancy is not a context where the wellness-adjacent peptide space operates on firm footing. The evidence base is thin for even some FDA-approved peptide drugs, and essentially nonexistent for the unapproved and compounded compounds that populate most online discussions. The default for nearly every peptide outside of insulin and a handful of tightly supervised clinical applications is: discontinue, disclose to your OB, and do not resume without explicit medical guidance.
That default is not pessimism. It is an honest acknowledgment of what "no human pregnancy data" actually means. Unknown risk during pregnancy is not the same as low risk — it is a gap that carries real consequences if the answer turns out to be unfavorable.
Our full peptide safety guide covers how FDA approval status and compounding regulation interact across the broader peptide landscape. For questions specific to your pregnancy, your OB or a maternal-fetal medicine specialist is the appropriate source. This article is not a substitute for that conversation.
Medical Disclaimer: This article is for general informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or qualified health provider with any questions you may have regarding a medical condition or medication use during pregnancy or breastfeeding. Never disregard professional medical advice or delay seeking it because of something you have read here.
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
